Clinical Trial Update: ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere [Phase 2, Phase 3]

View source ↗

Summary

This is an update on the ASCENT trial evaluating calcitriol in combination with Taxotere (docetaxel) for prostate cancer, specifically castration-resistant dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Calcitriol (calcitriol)
• Taxotere (docetaxel)

Snippet

Sponsor: Novacea | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: UNKNOWN